Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
15-19 June, 2025
Not Confirmed
Not Confirmed
15-19 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
15-19 June, 2025
Industry Trade Show
Not Confirmed
15-19 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
10 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/10/3096464/0/en/Gyre-Therapeutics-Announces-First-Dosing-in-Phase-1-Trial-of-F230-for-Pulmonary-Arterial-Hypertension-in-China.html
29 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/29/3090689/0/en/Gyre-Therapeutics-Announces-Closing-of-its-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html
22 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/23/3087217/0/en/Gyre-Therapeutics-Announces-Pricing-of-20-0-Million-Public-Offering-of-Common-Stock.html
22 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/22/3087081/0/en/Gyre-Therapeutics-Announces-Proposed-Underwritten-Public-Offering-of-Common-Stock.html
22 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/22/3087076/0/en/Gyre-Therapeutics-Hydronidone-Met-the-Primary-Endpoint-and-Demonstrated-Statistically-Significant-Fibrosis-Regression-in-Pivotal-Phase-3-Trial-for-the-Treatment-of-CHB-associated-L.html
09 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/09/3078051/0/en/Gyre-Therapeutics-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Update.html
ABOUT THIS PAGE